Erasca Corporate Presentation_2026-01.pdf

1、On a Journey to Erase CancerErasca Corporate PresentationJanuary 2026Eric and his wife Margaret,inspiring our bold mission to erase cancer2We caution you that this presentation contains forward-looking statements.All statements other than statements of historical facts contained in this presentation

2、,including statements regarding our future results of operations and financial position,business strategy,research and development plans,the anticipated timing(including the timing of initiation and the timing of data readouts),costs,design and conduct of our ongoing and planned preclinical studies

3、and clinical trials for our product candidates,the potential therapeutic benefits and potential patient population for each of our product candidates,our intellectual property protection,the timing and likelihood of success of our plans and objectives,the impact of the deprioritization of certain pr

4、ograms,and future results of anticipated product development efforts,are forward-looking statements.In some cases,you can identify forward-looking statements by terms such as“may,”“will,”“should,”“expect,”“plan,”“anticipate,”“could,”“intend,”“target,”“project,”“contemplates,”“believes,”“estimates,”“

5、predicts,”“potential”or“continue”or the negative of these terms or other similar expressions.The inclusion of forward-looking statements should not be regarded as a representation by us that any of our plans will be achieved.Actual results may differ from those set forth in this presentation due to

6、the risks and uncertainties inherent in our business,including,without limitation:our expectations regarding the potential therapeutic benefits of our product candidates,including ERAS-0015 and ERAS-4001,and our planned advancement of our development pipeline,including the anticipated timing of data